Navigation Links
Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty

ps and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit:

Debiopharm S.A. Contact    
Maurice Wagner
Director Corporate Affairs & communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69

Additional Media Contacts
In London
Brian Hudspith
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
2. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
3. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
4. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
5. Response Genetics, Inc. Announces Second Quarter Financial Results
6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
7. Westpak Announces New Cold Chain Test Division
8. Yongye International Announces Second Quarter 2012 Financial Results
9. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
10. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
11. BioMed Realty Announces New Brand Identity
Post Your Comments:
(Date:8/29/2014)... 2014 Three Lawrence Livermore researchers ... Hydrogen Production R&D Award for their research ... using sunlight. , Shared with collaborators from the ... of Nevada, Las Vegas (UNLV), the award recognizes ... photoelectrochemical solar-hydrogen production and corrosion processes. , These ...
(Date:8/28/2014)... 2014 SPIE Fellow Glenn Boreman, Professor ... Science and Director of the Center for Optoelectronics and ... Charlotte, and co-founder and Chairman of the Board of ... 2015 Vice President of SPIE, the international society for ... announced recent election results at the Annual General Meeting ...
(Date:8/28/2014)... research platform uses a laser to measure ... stress and heating, an approach likely to ... and batteries., This new technique, called nanomechanical ... and the surface stress of microscale structures ... the merits of surface-stress influence on mechanical ...
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from ... three key industry events beginning with Patient-Centered Clinical Trials ... in Boston , September 4-5. Patient recruitment ... and Aaron Fleishman will share insights on the ... a variety of tactics – from media to mobile apps ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... today published analyses of its second-generation map of ... markers than the initial version unveiled in 2005. ... consortium describes how the higher resolution map offers ... common diseases, explore the structure of human genetic ...
... FRANCISCO, Calif., Oct. 17 Monogram,Biosciences, Inc., (Nasdaq: ... on Wednesday, October 24, 2007 at 4:30 p.m. (Eastern ... will be hosted by Mr.,William D. Young, Chairman and ... teleconference, please call (877) 548-7912,or (719) 325-4878 for international ...
... ARNA ) today reported financial results for the ... the third quarter of 2007 were $5.0 million, compared,to ... revenues in the first,nine months of 2007 were $14.8 ... of 2006. Revenues in the first nine months of ...
Cached Biology Technology:Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7
(Date:8/31/2014)... infectious bacteria C. diff , that causes diarrhoea, ... team at the University of Leicester. , Using a ... is possible to identify the unique ,smell, of ... of the condition., What is more, the Leicester team ... of the disease simply from their smell a ...
(Date:8/31/2014)... MA -- Over the past several decades, malaria diagnosis has ... patient, a technician smears the blood across a glass slide, ... microscope for the Plasmodium parasite, which causes the disease. This ... in the blood an important measure of disease severity ... human error. , A research team from the Singapore-MIT Alliance ...
(Date:8/29/2014)... of Texas Medical Branch at Galveston has gone on record ... protect monkeys against a lethal dose of Ebola virus up ... disease is severe. , Thomas Geisbert, professor of microbiology and ... advances in Ebola treatment research. The filoviruses known as Ebola ... pathogens, with fatality rates of up to 90 percent. ...
Breaking Biology News(10 mins):Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2
... a traditional Chinese medicine having beneficial effects for people ... to back up the claims. A collaboration between Chinese, ... that the natural plant product berberine could be a ... roots and bark of a number of plants used ...
... are more prolific salt cedar eatersthan beetles from ... researchers hope. , Uzbekistan salt cedar beetles being ... same species as those released onthe salt cedar ... a differentcollection point, said Vanessa Carney, Experiment Station ...
... broader implications for understanding kidney disorders, genetics researchers ... a second gene that gives rise to Alagille ... organs. The Children's Hospital team previously discovered the ... researchers found that mutations in the NOTCH2 gene ...
Cached Biology News:Better beetle sought for salt cedar control 2Better beetle sought for salt cedar control 3Gene discovery may shed light on kidney disease 2
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: